14
views
0
recommends
+1 Recommend
0 collections
    3
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      New Year, Historical Mission, New Responsibility

      editorial

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Chinese Medical Journal (CMJ), founded in 1887 and the oldest medical journal in China, is one of our beloved journals. We began to read the journal from the days when we were medical students. We remembered Prof. Chuan-Han Feng, the former Editor-in-Chief's words: “The journal is mainly devoted to international communication, reporting the recent progress and achievements in preventive and clinical medicine and biomedical sciences, with experience characteristic of China in particular, to be shared by the world medical family.”[1] What Prof. Feng said 10 years ago is still the main mission of the journal today. When we have to obtain the information of “Cause-specific mortality for 240 causes in China during 1990–2013” from Lancet,[2] when we have to get the results of “National survey of drug-resistant tuberculosis in China” from New England Journal of Medicine,[3] we feel a great pressure. There is competition between international and local journals. Meanwhile, it is also a strong motivation for us to step forward. In the coming year, what is our main task? We should first realize that CMJ is of readers and authors. Our editorial office should identify our faithful readers and their needs through surveys done in hospitals, institutes, as well as scientific conferences. The interaction between readers and editorial office via our website is not always active. Mutual communication should be encouraged, and comments from readers should be collected and responded timely. Second, it is important for CMJ editorial office to gather our good authors with high citations. Reviewing the top cited article list in CMJ website, we were astonished that the top cited article is a case report titled “Bilateral papilloedema associated with lumbo-sacral intraspinal tumor.”[4] Case reports are indeed important for studying and teaching in rare diseases, but what we need more are high-qualified clinical studies such as randomized controlled trials and prospective cohort studies, which can be applied into recommendations for clinical practice. We feel happy to find that we have published a number of clinical studies of high quality: “Normative values of pulmonary function testing in Chinese adults,”[5] “A 5-year follow-up study on the pathological changes of gastric mucosa after Helicobacter pylori eradication,”[6] and “A randomized control trial on interruption of hepatitis B virus transmission in uterus.”[7] However, it is still far from enough. We understand that authors are more likely to publish their good work on more influential international journals such as Lancet or New Engl J Med. However, such journals can only publish a minority of them after all. As the top local journal, CMJ still has grand space to publish promising studies from a large amount of Chinese clinicians and scientists. Our editorial office can also get to know the authors, research teams, and their working progress through academic websites (ClinicalTrial.gov, Chinese Clinical Trial Registry, Cochrane, and PubMed) and invite the authors to submit their recent work to our journal. Authors may ask: Why should we submit our important work to CMJ? What is the difference of CMJ from other journals with higher impact factors? The answer is exactly what we are making our efforts to do so. Though we are living in a time that our work is evaluated by the impact factor of the journal where it is published, valuable work will never fade. CMJ has already earned the reputation in China by high quality, integrity, and novelty. CMJ not only tries to publish valuable work but also has the responsibility to help the studies known by readers and let their work cited by researchers throughout China and worldwide. We took the responsibility to help CMJ to earn reputation what it deserves. We will be successful when respected doctors and researchers are happy to publish their novel findings and thoughtful viewpoints on CMJ. It is our mission and responsibility.

          Related collections

          Most cited references6

          • Record: found
          • Abstract: found
          • Article: not found

          National survey of drug-resistant tuberculosis in China.

          The available information on the epidemic of drug-resistant tuberculosis in China is based on local or regional surveys. In 2007, we carried out a national survey of drug-resistant tuberculosis in China. We estimated the proportion of tuberculosis cases in China that were resistant to drugs by means of cluster-randomized sampling of tuberculosis cases in the public health system and testing for resistance to the first-line antituberculosis drugs isoniazid, rifampin, ethambutol, and streptomycin and the second-line drugs ofloxacin and kanamycin. We used the results from this survey and published estimates of the incidence of tuberculosis to estimate the incidence of drug-resistant tuberculosis. Information from patient interviews was used to identify factors linked to drug resistance. Among 3037 patients with new cases of tuberculosis and 892 with previously treated cases, 5.7% (95% confidence interval [CI], 4.5 to 7.0) and 25.6% (95% CI, 21.5 to 29.8), respectively, had multidrug-resistant (MDR) tuberculosis (defined as disease that was resistant to at least isoniazid and rifampin). Among all patients with tuberculosis, approximately 1 of 4 had disease that was resistant to isoniazid, rifampin, or both, and 1 of 10 had MDR tuberculosis. Approximately 8% of the patients with MDR tuberculosis had extensively drug-resistant (XDR) tuberculosis (defined as disease that was resistant to at least isoniazid, rifampin, ofloxacin, and kanamycin). In 2007, there were 110,000 incident cases (95% CI, 97,000 to 130,000) of MDR tuberculosis and 8200 incident cases (95% CI, 7200 to 9700) of XDR tuberculosis. Most cases of MDR and XDR tuberculosis resulted from primary transmission. Patients with multiple previous treatments who had received their last treatment in a tuberculosis hospital had the highest risk of MDR tuberculosis (adjusted odds ratio, 13.3; 95% CI, 3.9 to 46.0). Among 226 previously treated patients with MDR tuberculosis, 43.8% had not completed their last treatment; most had been treated in the hospital system. Among those who had completed treatment, tuberculosis developed again in most of the patients after their treatment in the public health system. China has a serious epidemic of drug-resistant tuberculosis. MDR tuberculosis is linked to inadequate treatment in both the public health system and the hospital system, especially tuberculosis hospitals; however, primary transmission accounts for most cases. (Funded by the Chinese Ministry of Health.).
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication.

            To investigate the relationship between H. pylori infection, gastric cancer and other gastric diseases through the changes in gastric mucosa and the status of different gastric diseases within 5 years after H. pylori eradication in H. pylori-positive subjects in a high incidence region of gastric cancer. One thousand and six adults were selected from the general population in Yantai, Shandong province, a high incidence region for gastric cancer in China. Gastroscopy and Campylobacter-like organism (CLO) testing were performed on all subjects. Biopsy samples from the gastric antrum and body were obtained for histology and assessment of H. pylori infection. All H. pylori-positive subjects were then randomly divided into two groups: treatment group receiving Omeprazole Amoxicillin Clarythromycin (OAC) triple therapy and placebo as controls. These subjects were endoscopically followed up in the second and fifth year. We compared the endoscopic appearance and histology of the biopsy specimens from the same site obtained at the first and last visits. All 552 H. pylori-positive subjects were randomly and evenly divided into treatment group or control group. During the five-year follow-up, the numbers of patients who continued to be negative or positive for H. pylori were 161 and 198, respectively. Statistical analysis revealed that: (1) At the initial visit, there were no significant differences in the severity and activity of inflammation, atrophy and intestinal metaplasia between the biopsy specimens from the antrum and body respectively in both groups. (2) The severity and activity of inflammation in both the antrum and body were markedly reduced after H. pylori eradication (P = 0.000). (3) Within five years after H. pylori eradication, intestinal metaplasia in the antrum either regressed or had no progression, while the proportion of intestinal metaplasia in the H. pylori-positive group increased significantly (P = 0.032). (4) After H. pylori eradication, the atrophy in both the antrum and body had no significant regression. The P value was 0.223 and 0.402, respectively. H. pylori eradication results in remarkable reduction in the severity and activity of chronic gastritis, marked resolution of intestinal metaplasia in the antrum. On the other hand, continuous H. pylori infection leads to progressive aggravation of atrophy and intestinal metaplasia.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              A randomized control trial on interruption of HBV transmission in uterus.

              To study the interruptive effect of hepatitis B virus (HBV) specific immunolobulin (HBIG) before delivery in attempt to prevent intrauterine transmission of HBV. Nine hundred and eighty HBsAg carrier pregnant women were randomly divided into HBIG group and control group. Each subject in the HBIG group received 200 IU or 400 IU of HBIG intramuscularly at 3, 2 and 1 month before delivery. The subjects in the control group did not receive any specific treatment. All newborn infants received 100 IU of HBIG intramascularly after venous blood samples were taken at birth and 2 weeks after birth, followed by 30 micro g plasma-derived HB vaccine or 5 micro g recombinant yeast-derived hepatitis B vaccine at 1, 2 and 7 months of age. Blood tests were performed for all the lying-in women and their neonates. Blood specimens were tested for HBsAg and HBeAg by enzyme immunoassay. All infants were followed up for 1 year. In the HBIG group, 491 neonates were born to 487 HBV carrier mothers; and in the control group, 496 neonates were born to 493 HBV carrier mothers. The rates of intrauterine transmission in the two groups were 14.3% and 5.7% respectively (chi(2) = 20.280, P < 0.001), and the rates of chronic hepatitis B in the two groups were 2.2% and 7.3% respectively (chi(2) = 13.696, P < 0.001). The high risk factors of intrauterine HBV infection included HBsAg HBeAg double positive and HBV DNA positive in the peripheral blood of pregnant women. HBV infection in the uterus may be interrupted by injecting multiple intramuscular HBIG injections before delivery without causing any side-effects.
                Bookmark

                Author and article information

                Journal
                Chin Med J (Engl)
                Chin. Med. J
                CMJ
                Chinese Medical Journal
                Medknow Publications & Media Pvt Ltd (India )
                0366-6999
                05 January 2016
                : 129
                : 1
                : 1-2
                Affiliations
                [1 ]Centre of Respiratory and Critical Care Medicine, China-Japan Friendship Hospital, Beijing 100029, China
                [2 ]Department of Respiratory Medicine, Capital Medical University, Beijing 100069, China
                [3 ]National Clinical Research Centre for Respiratory Disease, Beijing 100029, China
                [4 ]Beijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Beijing 100020, China
                Author notes
                Address for correspondence: Prof. Chen Wang, Centre of Respiratory and Critical Care Medicine, China-Japan Friendship Hospital, Beijing 100029, China Department of Respiratory Medicine, Capital Medical University, Beijing 100069, China National Clinical Research Center of Respiratory Medicine, Beijing 100029, China Beijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Beijing 100020, China E-Mail: cyh-birm@ 123456263.net
                Article
                CMJ-129-1
                10.4103/0366-6999.172542
                4797526
                26712424
                bf9d14e3-346e-49b5-a8b7-fc5318f6eec6
                Copyright: © 2015 Chinese Medical Journal

                This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

                History
                : 08 December 2015
                Categories
                Editorial

                chinese medical journal,impact factor,responsibility

                Comments

                Comment on this article